

**REMARKS***Status of the Claims*

Claims 1-123 are pending.

Claims 98, 99, 103, 106, 109, 111, 115, 118, 120 and 123 have been amended.

Claims 105, 108, 110, 117 and 119 have been canceled.

Rejection of non-elected subject matter

Claim 23 is rejected as drawn to an improper Markush group. Claim 23 has been amended and is now drawn to the elected subject matter.

Rejection pursuant to 35 USC § 112, second paragraph

Claims 98, 103, 109, 115 and 120 are rejected under 35 USC § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claims the subject matter which Applicants regards as the invention. The Examiner asserts that the terms “analog” and “analog thereof” are indefinite. The claims have been amended to delete the terms “analog” and “analog thereof.”

Claims 107-110 and 118-122 are rejected under 35 USC § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claims the subject matter which Applicants regards as the invention. The Examiner asserts that the term “pharmaceutical agent” is vague. Claims 107 and 118 have been amended to include specific pharmaceutical agents. Claims 108 and 119 have been canceled. Claims 109 and 120 have been amended to change claim dependency.

Applicants believe that the claims amendments overcome the Examiner’s rejections and withdrawal of this rejection is respectfully requested.

Rejection pursuant to 35 USC § 112, first paragraph

Claims 99-103, 105-115 and 117-122 are rejected under 35 USC § 112, first paragraph, as failing to comply with the enablement requirement. The Examiner assert that the claims contain subject matter, which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The Examiner asserts that the claimed

invention is not enabled so that any person skilled in the art can make or use the invention without undue experimentation.


The applicant disagrees with the Examiners statements regarding the scope of the diseases covered. However in order to expedite the allowance of this application claims 99, 106, 111, 118 and 123 have been amended and claims 98, 103, 105, 109, 110, 115, 117 and 120 have been canceled. It is believed that the current claims have overcome the Examiner's rejection and withdrawal of this rejection is respectfully requested.

### Conclusion

It is believed that the Claims are in condition for allowance, and it is respectfully requested that the application be passed to issue.

If the Examiner believes a telephonic interview with Applicants' representative would aid in the prosecution of this application, she is cordially invited to contact Applicants' representative at the below listed number.

Respectfully submitted,



Julie M. Lappin, Reg. No. 46,612

Pharmacia Corporation

of Pfizer, Inc

P.O. Box 1027

Chesterfield, MO 63006

(314) 274-2009

(314) 274-9095 (facsimile)